Description
ART6043 is an experimental oral medication being studied as a potential treatment for advanced or metastatic solid tumors, including colorectal cancer, particularly in patients whose tumors have specific genetic changes affecting DNA repair. It is being investigated in combination with olaparib (a PARP inhibitor). Clinical trials are currently enrolling patients to determine the right dose and assess the safety and effectiveness of ART6043 in this setting. The trials focus on patients with cancers that have defects in DNA repair pathways, such as those involving HER2 mutations.
Mechanism of Action
ART6043 is designed to target a specific protein involved in cancer cell growth and survival. It is being studied in combination with olaparib, which inhibits PARP enzymes. PARP inhibitors are often used in cancers with defects in DNA repair genes (like BRCA or HER2 mutations) because they can prevent cancer cells from repairing damaged DNA, leading to cell death. The specific protein targeted by ART6043 is being characterized in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.